Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06582381 · ClinicalTrials.gov registry record · NA

Evaluation of Biomarkers for Predicting Macronutrient Intake

A NA study of Glucose Metabolism and Amino Acid Metabolism, sponsored by Texas A&M University.

Recruiting
Registry status
NA
Development phase
33
Enrollment target
1
Study location

NCT06582381: Recruiting NA study of Glucose Metabolism and Amino Acid Metabolism, sponsored by Texas A&M University.

NCT06582381 is a NA study of Glucose Metabolism and Amino Acid Metabolism that is actively recruiting participants, run by Texas A&M University. The registered enrollment target is 33 participants, below the 53-participant average among 5 other Glucose Metabolism trials with a reported enrollment target (38% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06582381, a NA study of Glucose Metabolism and Amino Acid Metabolism, is actively recruiting participants, sponsored by Texas A&M University.

RECRUITING
Registry status
NA
Development phase
33 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical trial is to establish the relationship between macronutrient food intake and the resulting blood and intersticial fluid (ISF )levels of small molecule markers, as well as, validate wearable optical readers and data fusion algorithms to accurately predict individual-specific macronutrient availability in real time. The study involves 1 screening visit of approximately 2 hours and up to 4 study days of approximately 14 hours. Subjects will be asked to arrive in the fasted state on all study days. Fasting prior to screening is not required. On the screening visit, body weight, height, and body composition by Dual-energy X-ray absorptiometry (DXA) will be measured. In addition, habitual dietary intake, physical activity level (PASE), and quality of life (SGRQ-C) will be assessed.

Primary Outcome

Prediction models of postprandial plasma glucose in relation to the macronutrient content of predefined meals as assessed by plasma and/or ISF concentrations of amino acids, glucose, and/or triglycerides

Interventions

  • OTHER Meal set A
  • OTHER Meal set B
  • OTHER Meal set C
  • OTHER Meal set D

Study Locations (1)

Texas

  • Center for Translational Research in Aging & Longevity - College Station

Trial Details

FieldValue
Enrollment Target 33 participants
Start Date 2023-12-06
Est. Completion 2026-12
Phase NA
Texas A&M University

95 total trials

What NCT06582381 shows while recruiting

NCT06582381 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 53-participant average among 5 other Glucose Metabolism trials with a reported enrollment target (38% lower).

The record links to 2 conditions, with Glucose Metabolism appearing as the primary indexed condition, and to 4 interventions - of which Meal set A is the first listed.

NCT06582381 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT06582381 about?

NCT06582381 is a clinical study titled "Evaluation of Biomarkers for Predicting Macronutrient Intake". The goal of this clinical trial is to establish the relationship between macronutrient food intake and the resulting blood and intersticial fluid (ISF )levels of small molecule markers, as well as, validate wearable optical readers and data fusion algorithms to accurately predict individual-specific...

What is the current status of trial NCT06582381?

This trial is currently recruiting. It is a NA study. The enrollment target is 33 participants. The study started on 2023-12-06. Estimated completion is 2026-12.

What conditions does trial NCT06582381 study?

This clinical trial studies the following conditions: Glucose Metabolism, Amino Acid Metabolism.

What interventions are being tested in trial NCT06582381?

The interventions under investigation include: Meal set A (OTHER), Meal set B (OTHER), Meal set C (OTHER), Meal set D (OTHER).

Who is sponsoring clinical trial NCT06582381?

This trial is sponsored by Texas A&M University, which has 95 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06582381 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Glucose Metabolism

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02861898 · 33 participants · Phase 1

    Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma

  • NCT04871607 · 33 participants · Phase 2

    Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma

  • NCT05071937 · 33 participants · Phase 2

    ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer

  • NCT05168618 · 33 participants · Phase 2

    Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06582381, the US trial registry maintained by the National Library of Medicine. NCT06582381 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.